Market Overview

Shares of Intercept Pharma Rise as BofA Sees US, EU Regulators Giving A Thumbs Up

Share:
Related ICPT
Another Wild Ride In Intercept Pharmaceuticals
Morgan Stanley Downgrades Intercept Shares To Underweight, Cuts Target To $80
The Vetr community has upgraded $ICPT to 3.5-Stars. (Vetr)

On Monday, Bank of America released a bullish note on Intercept Pharmaceuticals (NASDAQ: ICPT). Shares trended higher throughout the session, spiking over the $440 level just minutes before the bell. The stock closed up nearly 8 percent.

Analyst Rachel McMinn believes the company should see FDA and EU regulators' support on using reversal of steatohepatitis, with no fibrosis progression, as surrogate histologic endpoint. Intercept's endpoint is to approve non-alcoholic steatohepatitis (NASH) drugs for the pre-cirrhotic population, according to the BofA analyst.

McMinn believes that regulators will need Phase 3 studies for approval, but regulators won't require CV outcomes data prior to approval.

Latest Ratings for ICPT

DateFirmActionFromTo
Apr 2016Morgan StanleyDowngradesEqual-weightUnderperform
Apr 2016BMO CapitalInitiates Coverage onOutperform
Apr 2016Wells FargoUpgradesMarket PerformOutperform

View More Analyst Ratings for ICPT
View the Latest Analyst Ratings

Posted-In: Analyst Color News FDA Analyst Ratings

 

Related Articles (ICPT)

View Comments and Join the Discussion!